Oncogenic activation of AKT-mTOR pathway also promoted PD-L1 expression and the combinational treatment of mTOR inhibitor and PD-L1 antibody inhibited tumor growth in syngeneic and genetically engineered mouse models of lung cancer [40]. The gene discussed is MTOR; the disease is neoplasm.